As ApoE4 promotes Aβ-mediated tau pathogenesis, neurodegeneration and microglial functions, ApoE down-regulation through IT delivery of di-siRNA is expected to be most beneficial in early and mild symptomatic (AD stages 3 & 4) APOE4/4 patients. The gene discussed is MAPT; the disease is Alzheimer disease.